Core Viewpoint - CICC initiates coverage on RiboBio-B (06938) with an "outperform" rating, setting a target price of HKD 100.0, indicating a 44.9% upside potential from the current stock price [1] Group 1: Company Overview - RiboBio is a global leader in small RNA drug development, possessing a proven and mature small RNA drug development platform [1] - Since its establishment in 2007, the company has developed the GalNAc liver-targeting RiboGalSTAR platform and is expanding from liver-targeting to extrahepatic targeting [1] - The company continuously iterates chemical modifications to enhance target specificity and sequence compatibility while reducing off-target effects, thereby improving efficacy and safety [1] - As of the end of 2025, RiboBio holds 473 patents and patent applications across major jurisdictions, establishing a comprehensive intellectual property portfolio [1] - The company's R&D platform integrates the entire technology chain, ensuring efficiency in pipeline advancement from CMC production and early research to commercialization [1] Group 2: Clinical Assets - RiboBio is one of the Chinese small RNA companies with the most clinical assets, having 7 siRNA candidates in clinical stages as of the end of 2025, with 4 in Phase II [2] - Core assets include RBD4059 (FXI), RBD5044 (ApoC3), and RBD1016 (HBV) [2] - RBD4059 is the world's first and fastest clinical FXI siRNA drug for treating thrombotic diseases, expected to enter Phase IIb clinical trials in 2026 [2] - RBD5044 is the second siRNA targeting ApoC3 to enter clinical stages, following Arrowhead [2] - RBD1016 is currently being evaluated for its drugability in HBV [2] Group 3: Market Perspective - The main difference between the firm and the market is the belief in the drugability of FXI inhibitors, particularly for conditions like stroke and post-knee replacement surgery, which have validated drugability [3] - FXI siRNA is expected to tackle atrial fibrillation indications due to its higher target inhibition rate [3] Group 4: Potential Catalysts - Potential catalysts include data mapping for FXI inhibitors and ApoC3 siRNA, as well as the initiation of Phase II clinical trials and data readouts for multiple small RNA drugs from RiboBio [4]

Core Viewpoint - The article discusses the significant decline in the stock prices of ten high-issue-price stocks in the A-share market, with seven of them falling below their issue prices, highlighting the risks associated with high valuations and market sentiment shifts [1][22]. Group 1: Stock Performance - Among the ten stocks, only Stone Technology, Naxin Micro, and BeiGene remain above their issue prices as of mid-February 2026 [6][8]. - The maximum decline from issue prices includes: - CanSino down 69.15% - Wanrun New Energy down 58.54% - Huabao New Energy down 54.93% - Yiqiao Shenzhou down 42.22% - Hemai down 32.82% - Foxit Software down 22.17% - Suocheng Technology down 12.83% [10]. - CanSino experienced a dramatic drop of 93% from its peak price of 797.20 yuan to 63.90 yuan [11][19]. Group 2: Company Backgrounds - Hemai, the highest issue price stock at 557.80 yuan, faced a significant decline after reaching a peak of 1877.43 yuan [12]. - Wanrun New Energy, listed at 299.88 yuan, never reached its issue price after its first day of trading [15]. - Yiqiao Shenzhou, with an issue price of 292.92 yuan, peaked at 353.83 yuan before falling to 73.38 yuan [16]. - CanSino, a COVID-19 vaccine stock, was listed at 209.71 yuan and peaked at 797.20 yuan before its decline [17]. Group 3: Market Conditions and Trends - The high issue prices were driven by market enthusiasm for sectors like hard technology, new energy, and biomedicine during the registration reform period from 2020 to 2023 [5][4]. - The overall market sentiment has shifted, leading to a decline in these stocks as the initial excitement waned [22]. - The article notes that the current new stock market shows a stark contrast, with a recent increase in participation and initial gains, but also warns of accumulating risks [24][26]. Group 4: Investment Implications - The high issue prices and P/E ratios of these stocks are no longer guarantees of company strength, but rather potential warning signs of investment risk [28]. - The article emphasizes that the era of easy profits from new stock subscriptions has ended, requiring more thorough research and disciplined investment strategies [27].

格隆汇2月19日｜莫德纳表示，已与监管机构展开进一步磋商，并宣布美国食品药品管理局(FDA)将受 理该公司采用mRNA技术的流感疫苗上市申请。就在上周，该监管机构以研究设计存在缺陷为由，拒绝 受理莫德纳这款新型流感疫苗的审核申请。但据公司称，在后续沟通中，FDA改变立场，同意启动审核 流程。 ...

经济观察网 天演药业公布了2026年的业务进展及年度目标，包括多项临床数据公布与研发计划。 截至2025年12月31日，公司现金及现金等价物为7,450万美元（未经审计），预计可支持运营至2027年 底，为上述计划提供资金保障。 以上事件均基于公司公开披露的计划，具体时间及结果需以实际公告为准。 产品研发进展 患者入组完成：预计完成muzastotug随机2期剂量优化研究的患者入组，该研究旨在为3期临床试验确定 最优给药方案。 业务拓展：公司表示将持续推进合作与授权协议，包括与赛诺菲、Third Arc Bio等合作伙伴的项目进 展。 财务状况 近期事件 2026年第一季度：计划公布muzastotug（ADG126）联合帕博利珠单抗治疗三线及以上微卫星稳定型结 直肠癌（MSS CRC）患者的1b/2期更新研究数据，包括10 mg/kg剂量组（41例患者）和20 mg/kg剂量组 （26例患者）的结果。 同期：将分享与罗氏合作的临床研究结果，评估muzastotug联合阿替利珠单抗及贝伐珠单抗用于肝细胞 癌（HCC）一线治疗的疗效与安全性。 新增数据披露：公布muzastotug联合帕博利珠单抗及标准治疗（呋 ...

Core Insights - The company, Weili Zhibo, focuses on three core technology platforms targeting tumors and autoimmune diseases, including LeadsBody, X-body, and TOPiKinetics [1] - LBL-024 has a broad indication layout with 12 indications and 9 ongoing clinical trials, including a pivotal study expected to submit a BLA by Q3 2026 [1] - LBL-034 is currently in a Phase II study with promising safety and efficacy data across four patient populations, including those with relapsed refractory multiple myeloma [2] Company Developments - The company has established seamless capabilities in early research, translational medicine, clinical development, CMC, and business expansion [1] - Two autoimmune disease products have achieved overseas collaboration, with LBL-047 having enrolled its first patient and LBL-051 planning to submit a clinical application to the FDA in Q1 2026 [2] Financial Projections - Revenue forecasts for 2025-2027 are estimated at 175.0 million, 196.0 million, and 200.8 million, reflecting year-on-year growth of -/12.0%/+2.4% [2] - The current stock price corresponds to PS ratios of 62, 55, and 54 for the respective years [2] - The company is expected to experience significant clinical data catalysts in 2026, with a potential commercialization inflection point in 2027 [2]

来源：经济观察网 经济观察网 根据截至2026年2月17日的公开信息，科兴生物（Sinovac Biotech Ltd.，美股代码：SVA） 作为一家在纳斯达克上市的疫苗企业，近期有以下几个值得关注的事件进展。需注意，科兴生物 （SVA）与A股科兴制药（688136）为独立上市公司。 股票近期走势 合同最新进展 2025年11月，科兴生物与巴西卫生部签署价值超7亿美元的疫苗供应合同，计划在未来10年内提供水痘 和狂犬疫苗。合同执行情况（如生产交付、收入确认）将是衡量公司海外业务复苏能力的关键指标。 以上内容基于公开资料整理，不构成投资建议。 公司结构与治理 与科兴生物控股层面相关的股东会议争议案庭审定于2026年4月下旬至5月初进行，涉及董事会职权归属 问题。该案结果可能间接影响上市公司治理结构，需关注其对公司运营稳定性的潜在波及。 科兴生物因未能在延长期限内提交2024年年度报告，于2025年11月收到纳斯达克退市决定函。公司表示 将申请听证会进行申辩，若未获批准，股票可能被暂停交易并退市。退市与否的最终决定是当前最受关 注的风险事件，其进展直接影响投资者对股票流动性和公司治理稳定性的预期。 ...

格隆汇2月16日丨复宏汉霖(02696.HK)宣布，近日，公司自主研发的HLX15-SC(重组抗CD38全人单克隆 抗体注射液－皮下注射)(「HLX15-SC」)用于多发性骨髓瘤治疗的1期临床试验申请(IND)获美国食品药 品管理局(FDA)批准。 ...

根据IQVIA MIDASTM的资料(IQVIA是全球医药健康产业专业信息和战略咨询服务提供商)，2024年 度，达雷妥尤单抗于全球範围内的销售额约为128.8亿美元。 HLX15(重组抗CD38全人单克隆抗体)(HLX15)是本公司自主研发的达雷妥尤单抗生物类似药，拟用于多 发性骨髓瘤(MM)等治疗。达雷妥尤单抗是一种人源化的抗CD38的IgG1κ单克隆抗体，其可与肿瘤细胞 表面表达的CD38结合，通过补体依赖的细胞毒作用(CDC)、抗体依赖的细胞毒作用 (ADCC)和抗体依赖 的细胞吞噬作用(ADCP)、以及Fcγ受体等多种免疫相关机制诱导肿瘤细胞凋亡。除此之外，达雷妥尤单 抗还可通过降低髓源性抑制细胞和消耗CD38表达阳性的免疫调节性T、B细胞来达到减少MM细胞的作 用。2024年6月，HLX15-IV(静脉注射制剂)在中国男性健康受试者中开展的 1期临床研究已成功完成。 2026年2月，HLX15-SC用于多发性骨髓瘤治疗的 1期临床试验申请(IND)获国家药品监督管理局(NMPA) 批准。2025年2月，本公司与Dr. Reddy's Laboratories Ltd.的全资附属公司Dr. Redd ...

Core Viewpoint - The stock price of Valiant Bio-B (09887) increased by 7.91% to HKD 66.20, with a trading volume of HKD 28.44 million following the announcement of its inclusion in the Hang Seng Composite Index [5]. Group 1: Stock Performance - Valiant Bio-B's stock price rose by 7.91% to HKD 66.20 [5]. - The trading volume reached HKD 28.44 million [5]. Group 2: Index Inclusion - On February 13, the Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series, including Valiant Bio-B in the Hang Seng Composite Index [5]. - The changes will be implemented after the market closes on March 6, 2026, and will take effect on March 9, 2026 [5]. - The inclusion may lead to adjustments in the Hong Kong Stock Connect investment scope, as Valiant Bio-B meets various criteria such as market capitalization, liquidity, and listing duration [5]. Group 3: Clinical Research - Valiant Bio-B announced the successful administration of its drug, ViliXin™ (PD-L1/4-1BB bispecific antibody, LBL-024), to the first patient in an Ib/II clinical trial for treating recurrent or metastatic triple-negative breast cancer [5]. - The open-label, multicenter Ib/II clinical study is led by Professor Yin Yongmei from Jiangsu Provincial People's Hospital and is being conducted at multiple hospitals nationwide [5]. - The trial aims to evaluate the efficacy and safety of ViliXin™ either as a monotherapy or in combination with albumin-bound paclitaxel for patients with recurrent or metastatic triple-negative breast cancer [5].

Group 1 - The core point of the article is that Beihai Kangcheng-B (01228) experienced a significant stock price increase, rising over 17% at one point and closing up 8.6% at HKD 3.03, with a trading volume of HKD 26.6484 million [1] - On February 16, Beihai Kangcheng announced a placement of 84.0336 million new shares to a wholly-owned subsidiary of WuXi Biologics, representing approximately 14.12% of the company's enlarged issued share capital, at a price of HKD 2.38 per share, which is a discount of about 14.7% compared to the closing price of HKD 2.79 on February 13 [1] - The net proceeds from the placement are expected to reach HKD 199 million, with approximately 60% allocated for settling the group's trade payables, around 28% for research and development expenses for existing product lines, and the remaining 12% for working capital and regulatory maintenance of commercialized products [1]